glp 1 agonist plants GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous GLP-1 production and L-cell differentiation | Diabetology & Metabolic Syndrome The Role of GLP-1RA Medications
Description
In Q4 2024, US ZEPBOUND revenue reached USD 1.91 billion , a significant increase from USD 175.8 million in Q4 2023
the fasting and post-prandial GLP-1 levels decreased to an even lower value from baseline levels at 47 years post SG [23]
Many more GLP-1 drugs are in development
2020;5(6):e133429
Weight management/metabolic effects: GLP-1 RAs may also support weight management in adults with type 2 diabetes who are overweight or obese, providing an added metabolic advantage alongside their primary glycaemic and cardioprotective effects
